New insights into the role of empagliflozin on diabetic renal tubular lipid accumulation

BACKGROUND: Glucose cotransporter (SGLT) 2 suppression provides potent renal protective effect during diabetic kidney disease (DKD). This work aimed to explore how empagliflozin (EMPA, the selective and strong inhibitor of SGLT2) affected renal lipid deposition among patients undergoing type 2 diabe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hong, Chen, Juan, Hua, Yulin, Zhang, Yuyang, Liu, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396853/
https://www.ncbi.nlm.nih.gov/pubmed/35999610
http://dx.doi.org/10.1186/s13098-022-00886-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396853/
https://www.ncbi.nlm.nih.gov/pubmed/35999610
http://dx.doi.org/10.1186/s13098-022-00886-x

Ejemplares similares